Heart attack

Molecular therapy for attenuating  pathogenesis associated with  Myocardial infarction: Ciglitazone, an anti-hyperglycemic drug, decreases GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, and promotes heart healing via up regulation of its target gene, 3/November/2017, 7.10 am
Molecular therapy for attenuating  pathogenesis associated with  Myocardial infarction: Ciglitazone, an anti-hyperglycemic drug, decreases GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, and promotes heart healing via up regulation of its target gene, 3/November/2017, 7.10 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; and Center for Systems Biology, Massachusetts General Hospital…

read more

Molecular therapy for attenuating  pathogenesis associated with  Myocardial infarction: Glimepiride, an anti-diabetic medication, decreases GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, and promotes heart healing via up regulation of its target gene, 30/October/2017, 9.09 am
Molecular therapy for attenuating  pathogenesis associated with  Myocardial infarction: Glimepiride, an anti-diabetic medication, decreases GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, and promotes heart healing via up regulation of its target gene, 30/October/2017, 9.09 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; and Center for Systems Biology, Massachusetts General Hospital…

read more

Natural product-derived therapy for Myocardial Infarction: Kaempferol-3-O-rutinoside, isolated from Solidago virgaurea – European Goldenrod, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS, 29/October/2017,  9.16 am
Natural product-derived therapy for Myocardial Infarction: Kaempferol-3-O-rutinoside, isolated from Solidago virgaurea – European Goldenrod, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS, 29/October/2017,  9.16 am 960 720 Dr Boomi's Genom-2-Discovery Center

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of Nature,  by Prof Dimmler, Boon, and others. What we…

read more

Molecular therapy for attenuating pathogenesis of Myocardial infarction: Netoglitazone, an anti-diabetic medication, decreases GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, and promotes heart healing via up regulation of its target gene, 28/October/2017, 1.16 am
Molecular therapy for attenuating pathogenesis of Myocardial infarction: Netoglitazone, an anti-diabetic medication, decreases GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, and promotes heart healing via up regulation of its target gene, 28/October/2017, 1.16 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; and Center for Systems Biology, Massachusetts General Hospital…

read more

Cardiac rejuvenation therapy: A therapeutic mix encompassing  Rivaroxaban and Asprin (RA)  suppresses tumor suppressor INK4a/p16 expression, promotes cardiac repair, delays cardiac ageing and senescence, and extends life span via up regulation of its target gene, 28/October/2017, 12.26 am
Cardiac rejuvenation therapy: A therapeutic mix encompassing  Rivaroxaban and Asprin (RA)  suppresses tumor suppressor INK4a/p16 expression, promotes cardiac repair, delays cardiac ageing and senescence, and extends life span via up regulation of its target gene, 28/October/2017, 12.26 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A recent study from the Population Health Research Institute, McMaster University and Hamilton Health Sciences, David Braley Research Bldg., Hamilton General Hospital, 237 Barton St. E.,…

read more

Molecular therapy for attenuating pathogenesis of Myocardial infarction: Lobeglitazone, an anti-diabetic medication, decreases GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, and promotes heart healing via up regulation of its target gene, 27/October/2017, 12.55 am
Molecular therapy for attenuating pathogenesis of Myocardial infarction: Lobeglitazone, an anti-diabetic medication, decreases GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, and promotes heart healing via up regulation of its target gene, 27/October/2017, 12.55 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; and Center for Systems Biology, Massachusetts General Hospital…

read more
Start Typing